New Orleans BioInnovation Center的动态

The World CB & CDx Summit in Boston is off to a great start! Swing by Booth 22 to visit our team and say hello! ?? And be sure to catch Azad Gucwa, Ph.D., MT(ASCP) tomorrow at 2:20p ET, she'll be presenting on: ? Leveraging single-cell multi-modal analysis to get a more comprehensive view of multiple myeloma disease progression, therapy response and resistance, and therapy safety & efficacy ? Integrating SNVs, zygosity, CNVs, VDJ clonotype, and surface immunophenotype at the single-cell level, while measuring the transduction efficiency and vector copy number of potential CAR-T therapies ? Assessing genome integrity through genome-wide CNV analysis at the single-cell level and leverage cohort-level analysis to guide therapeutic and clinical development

In this episode of “Answers From the Lab,” Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, Inc., is enhancing the care and quality of life for patients affected by systemic lupus erythematosus. https://bit.ly/4e9aXt0

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer’s disease and cognitive impairments, and how laboratorians can responsibly help shape the future of healthcare. https://bit.ly/3WeqAck

My PhD thesis work focused on studying the impact of bacterial functional amyloids, like CsgA, in Parkinson's disease causation. Extremely delighted to see that novel therapeutics are being developed to target the gut-brain-axis in neurodegenarative diseases. #gutmicrobiome #gutbrainaxis #neurodegeneration #parkinsonsdisease #alzheimersdisease

Today, on Rare Disease Day 2024, we reflect on the challenges and complexities within the realm of rare diseases. Despite these hurdles, at Treeway, our commitment to advancing treatments for amyotrophic lateral sclerosis (ALS) remains unwavering. ? For the ADORE study, in which our lead product TW001 was tested in ALS, we thoroughly discussed and planned the study design with ALS investigators worldwide, #TRICALS, European Medicines Agency and FDA ánd ALS patients to ensure a balanced approach to efficacy and safety endpoints, study duration, and patient numbers in an orphan disease like ALS. ? The ADORE study, executed and sponsored by our pharma partner Ferrer, which was one of the largest ALS clinical studies ever conducted in Europe, was anticipated to yield positive results by all parties involved. However, reality proved different as the study did not meet its primary outcome. This outcome is not only a disappointment for patients and their loved ones but also for the dedicated healthcare professionals in ALS, and of course for our pharma partner Ferrer and ourselves. ? From a scientific perspective, and ultimately for the future ALS patients, this information is invaluable. Despite this setback, our goal remains unchanged. We aim to resiliently move forward so that Treeway can continue to exist and advance the development of new ALS therapies. These challenges remind us that the path to medical breakthroughs is often paved with obstacles, but we remain steadfast in our mission. By learning from this experience and collaborating with the ALS community, we will intensify our efforts and continue to strive towards a future where ALS is no longer a devastating diagnosis. #OrphanDisease #RareDiseaseDay2024 #ALSResearch #Treeway #NeverGiveUp

What are the latest advancements in #Alzheimers disease testing and treatment? Listen to Bobbi Pritt and William Morice II, MD, PhD from Mayo Clinic Laboratories to learn more.

Blood biomarkers for a full metabolic profile. How can Nightingale's panel boost Alzheimer's and Parkinson's research. Let's discuss at #AD/PD #nightingalehealth #metabolomics

September 13th is World Sepsis Day – get in touch with ARTCLINE at DGAI and DGTI 2024! Sepsis mortality remains alarmingly high, despite continuous research and development by the medical and scientific community. ARTCLINE is targeting the crucial late-stage phase of septic shock, where immune suppression occurs due to a paralyzed immune system. Our patented extracorporeal ARTICE? system uses immune cells from healthy donors to disburden and reactivate the patient’s dysfunctional immune system. Clinical studies have demonstrated clinical benefit of ARTICE?. Currently a multi-center, randomized, controlled, clinical trial enrolling up to 142 patients is active in leading ICUs in Germany. Stay tuned for interim results that will be available by the end of this year! Join us at our booths to meet the team and discover how ARTICE?, an immune cell-based extracorporeal therapy, strengthens the immune competence of patients in septic shock! ?? DGTI 2024 – Düsseldorf ??? September, 11th – 13th ?? Booth number: 1 Poster P-15-10:?Prolonged storage of purified granulocyte concentrates from pooled buffy coats (Dr. Jens Altrichter) ? ?? DGAI 2024 – Kassel ??? September, 11th – 13th ?? Booth number: 119 #DGAI2024 #DGTI2024 #Innovation # #Technology #ARTICE #Sepsistreatment #Sepsis #septicshock #wefightsepsis

As September’s Pulmonary Fibrosis Awareness Month comes to an end, our commitment at Boehringer Ingelheim to addressing unmet medical needs continues – not just for patients today, but for generations to come. Building on our heritage in this space, we have a deep understanding of pulmonary fibrosis, its heterogeneity, molecular pathways, biomarkers, and the mechanisms of fibrosis.?Our ambition is to continue to lead the science and go beyond slowing progression, to hopefully restore health and to potentially prevent progression in early disease. We know we can’t do it alone. We are committed to forging partnerships and exploring new avenues to turn a brighter future into a tangible reality for patients. #PulmonaryFibrosis #ResearchandDevelopment

What are the latest advancements in Alzheimer’s disease testing and treatment? Listen to @parasitegal and @moricemdphd to learn more.